XML 45 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Corporate and Group Information
 12 Months Ended
Dec. 31, 2024
Corporate and Group Information [Abstract]  
CORPORATE AND GROUP INFORMATION
1.CORPORATE AND GROUP INFORMATION

 

Adlai Nortye Ltd. (the “Company”) is a limited liability company incorporated in the Cayman Islands on 9 May 2018. The registered office of the Company is located at Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman, KY1-1002, Cayman Islands.

 

The Company is an investment holding company. The Company through its subsidiaries (collectively, the “Group”) were involved in the research and development of pharmaceutical products.

 

As of the date of this report, the Company had direct and indirect interests in its subsidiaries, all of which are private limited liability companies, the particulars of which are set out below:

 

                Percentage    
                of equity    
        Date and place of   Issued ordinary   attributable to    
        incorporation / registration   share/   the Company    
Name   Notes   and place of operations   registered capital   Direct   Indirect   Principal activities
Alpine Bioscience Ltd. (“Alpine BVI”)       British Virgin Islands 8 January 2018   One share of par value $1   100 %   —   Investment holding
Adlai Nortye USA Inc (“Adlai US”)       The United States 30 January 2018   10,000 shares of par value $0.0001 each    —   100 %   Clinical studies and testing, and technology development and transfer
Adlai Nortye (Switzerland) AG (“Adlai Swiss”)       Switzerland 21 June 2022   100 shares of par value CHF1’000 each    —   100 %   Investment holding
Adlai Nortye PTE.LTD (“Adlai SGP”)       Singapore 22 April 2022   Two shares of par value $1    —   100 %   Investment holding
Adlai Nortye (HK) Limited (“Adlai HK”)       Hong Kong 24 April 2018   HKD 0.001    —   100 %   Investment holding
Adlai Nortye Biopharma Co., Ltd* (“Adlai Hangzhou”)       the People’s Republic of China (“PRC”)/Mainland China 14 September 2004   RMB 200,000    —   100 %   Product research and development, technology transfer and consulting services business
Shanghai Adlai Nortye Biopharma Co., Ltd* (“Adlai Shanghai”)       the People’s Republic of China (“PRC”)/Mainland China 22 December 2021   RMB 10,000    —   100 %   Product research and development, technology transfer and consulting services business
*The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.